Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Charles River Laboratories Intl. Inc (CRL) vs Abrdn Physical Platinum Shares ETF (PPLT) Price & Performance

Charles River Laboratories Intl. IncTrade
Abrdn Physical Platinum Shares ETFTrade

Price performance (Past 24H)

Key statistics

Charles River Laboratories Intl. Inc vs Abrdn Physical Platinum Shares ETF — how do they compare? Charles River Laboratories Intl. Inc trades at $282.01 (market cap $13.22B), while Abrdn Physical Platinum Shares ETF trades at $16. The key difference: Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Abrdn Physical Platinum Shares ETF nearer its low. Which is the better fit depends on your goals.

CRLPPLT
Market Cap
$13.22B
Sector
HealthCommodities - Metals/Agriculture
52-Week High
$282.00$25.23
52-Week Low
$145.57$11.95
Enterprise Value
$16.06B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Charles River Laboratories Intl. Inc

Charles River Laboratories (CRL) trades at $267.49, up 0.75% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q2 2026 earnings, beating estimates with EPS of $3.02 versus $2.77 expected, and raised full-year guidance. Despite negative net income margins and high valuation multiples, analyst sentiment remains overwhelmingly positive with 72% buy ratings.

CRL shows operational strength with consistent earnings beats and improved demand, yet faces risks from high debt and profitability challenges. The consensus price target of $277.29 suggests modest upside, but investors must weigh growth prospects against valuation concerns and macroeconomic pressures on biotech spending.

Abrdn Physical Platinum Shares ETF

PPLT trades at $15.85, up 1.15% today, with a bullish technical signal from moving averages but a neutral reading from oscillators. The stock is set for a 1:10 stock split effective May 18, 2026. Recent news highlights platinum's underperformance versus gold and silver, positioning PPLT as a potential catch-up trade in the precious metals sector.

The outlook for PPLT hinges on a potential rebound in platinum prices, supported by positive sentiment from recent geopolitical developments. Key risks include continued commodity price volatility and the ETF's lack of dividend income, which may deter yield-seeking investors despite its strong past performance.

Returns comparison

Trailing returns across standard periods

About Charles River Laboratories Intl. Inc

Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.

Read more on CRL

About Abrdn Physical Platinum Shares ETF

PPLT is a physically-backed ETF designed to track the spot price of platinum, less the Trust's expenses. It holds physical platinum bullion in secure vaults, providing investors with a liquid and cost-effective way to access the platinum market without the logistical challenges of direct ownership.

Read more on PPLT